Abstract High-density lipoprotein (HDL) cholesterol (HDL-C) levels are a strong inverse predictor of atherosclerosis risk, but the physiological determinants of HDL-C levels are poorly understood. We selected 57 human subjects (30 women and 27 men) with a broad range of HDL-C levels and performed turnover studies of apolipoprotein (apo)A-I and apoA-II, the two major apolipoproteins of HDL, to measure the fractional catabolic rate (FCR) and production or transport rate (TR) of these proteins. We also measured several other parameters known to correlate with HDL-C levels to test for their interrelations and to postulate mechanisms of regulation of HDL-C levels. As expected, the women had higher levels of HDL-C (56.7+21.4 versus 45.1±16.3 mg/dL, mean+SD; P=.O3) and apoA-I (147±32 versus 126±29 mg/ dL, P=.O1) than men and did not differ in apoA-II levels (34.5±7.4 versus 33.3±7.5 mg/dL, P>2).
H igh-density lipoprotein (HDL) cholesterol
(HDL-C) levels are well established as an inverse risk factor for atherosclerosis, 12 but the regulation of HDL-C levels is only beginning to be understood. Earlier HDL turnover studies suggested that the fractional catabolic rate (FCR) of apolipoprotein (apo)A-I is elevated in subjects with low HDL-C 34 and that apoA-I FCR correlates with HDL-C, 56 but other investigators reported that apoA-I transport rate (TR) may better explain variability in HDL-C 7 or apoA-I levReceived June 19, 1992 ; revision accepted February 8, 1994 . From the Laboratory of Biochemical Genetics and Metabolism, The Rockefeller University, New York, NY, and Hadassah University Hospital (S.E.), Jerusalem, Israel.
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stepwise multiple linear regression analysis, apoA-I FCR alone accounted for 66% of the variability in HDL-C; two other variables accounted for an additional 7%. Due to the importance of apoA-I FCR, its determinants were sought among the remaining variables. Two estimates of HDL size or density, the HDL-C/apoA-I+apoA-II ratio and the percent of the apoA-I tracer found in the d>\2\ g/mL fraction, correlated strongly with apoA-I FCR in single linear regression (r=-.81 and .62, respectively; P<.0001 for both), and in stepwise multiple linear regression they accounted for 70% of the variability in apoA-I FCR. The waist-to-hip ratio predicted another 2% of the variability. Major correlates of HDL-C/ apoA-I+apoA-II were fasting triglyceride levels and the activity ratio of lipoprotein lipase to hepatic lipase, which together predicted 72% of the variability. Waist-to-hip ratio and fasting insulin together predicted 46% of the variability of triglyceride levels and waist-to-hip ratio alone predicted 26% of the variability in the ratio of lipoprotein lipase to hepatic lipase. Based on these correlations, we hypothesize that abdominal fat, insulin sensitivity, lipase activity, and plasma triglyceride levels may regulate HDL size, which appears to be the primary determinant of apoA-I FCR, which may, in turn, be the major determinant of HDL-C levels. These factors appear to play crucial roles in the regulation of HDL-C levels and may be important in determining susceptibility to atherosclerosis. 8 This inconsistency, as well as the small number of subjects and the small range of HDL-C levels in most of these studies, has caused uncertainty in the interpretation of these data. Studies of subjects with high 9 and low 10 HDL-C levels and employing both high and low fat intake 11 have established that apoA-I FCR is the primary metabolic predictor of intersubject variability in HDL-C levels and have suggested that HDL size or density, as possibly influenced by fasting triglyceride (TG) levels and endothelial lipase activity, may be a key determinant of apoA-I FCR and hence of HDL-C levels. Nevertheless, knowledge of these relations remains preliminary.
Despite the evident importance of the gender differences in HDL-C and apoA-I levels, the metabolic basis of this difference has been incompletely explored. One study reported a significantly higher apoA-I TR in women with no difference in apoA-I FCR, 6 and another smaller study found nonsignificant trends toward lower TR and FCR of apoA-I in women. 12 Many studies have shown an inverse correlation between abdominal adiposity (most commonly measured by the waist-to-hip ratio) and HDL-C levels (see Reference 13 for review), but the relationship between body fat distribution and HDL metabolism, as measured by apolipoprotein turnover, is just beginning to be explored. The FCRs of apoA-I and apoA-II have correlated positively with chest skinfold thickness 14 ; however, abdominal fat, as measured by the waist-to-hip ratio, may better predict lipoprotein metabolism and atherosclerosis risk (see Reference 15 for review), and the relation of this measure to HDL metabolism remains unknown. Fasting insulin levels have been associated with increased apoA-I FCR in diabetic 16 and hypertensive 17 subjects, but the relevance of insulin levels to HDL metabolism in a normoglycemic and normotensive population has not been reported, and the potential mechanisms of an insulin effect on HDL metabolism are unclear.
This study was designed to explore the metabolic regulation of HDL-C levels by analyzing HDL apolipoprotein turnover data and related parameters in a sufficient number of subjects to allow multivariate statistical analysis. The larger sample size also allowed comparisons between men and women as well as samegender analysis. The extensive subject population of the current study was obtained by combining narrower groups of subjects from previous smaller studies 911 with many new subjects and by including new data on all subjects. We found that women and men differ more clearly in FCR than in TR of HDL apolipoproteins. Relative amounts of abdominal fat by waist-to-hip ratio correlated directly with apolipoprotein HDL FCR. We hypothesized an ordered hierarchy of factors that might regulate HDL-C levels. Multiple linear regression analysis of the extended data set in this study was consistent with this hypothetical hierarchy, suggesting that these interacting factors may constitute a major mechanism of antiatherogenesis.
Methods Subjects
Thirty female and 27 male subjects were recruited for HDL metabolic studies from three sources: (1) patients from the clinic of the Laboratory of Biochemical Genetics and Metabolism; (2) healthy adult volunteers working on the staff at The Rockefeller University or at neighboring institutions; and (3) undergraduate students in a work-study program. The subjects were recruited to obtain as broad a distribution of HDL-C and TG levels as possible. All subjects were free from hepatic, renal, thyroid, and immunologic disorders by history and laboratory screening and had normal brachial diastolic blood pressure by examination. Studies on 21 subjects (Nos. 6, 9, 17, 19, 20, 26, 30 through 33, 35 through 37, 41, 42, 44, 45, 47, 48, 54 , and 55) are presented for the first time in this article, and individual data are given for the first time for an additional two subjects, Nos. 39 and 40. Turnover data from the other subjects have been reported in studies of elevated HDL-C in women, 9 of dietary effects on HDL turnover, 11 and of low HDL-C in men and women. 10 Subject No. 23 took 5 mg glyburide, an oral hypoglycemic, each morning. Subject No. 6 used insulin, 2 U regular and 8 U NPH, subcutaneously each morning. Both were on stable dosage regimens throughout the study and had been taking their respective medications for several years. These two subjects were omitted from the statistical analysis of correlations between fasting insulin levels and the other study parameters. One subject (No. 37) had a history of hypertension and had been treated with metoprolol, a /3-blocker, and verapamil. The /3-blocker was discontinued 2 weeks before the turnover study, and the subject's blood pressure remained normal throughout the study period. None of the other subjects took medications known to alter glucose or lipid levels.
The clinical aspects of these studies were approved by the Institutional Review Board of The Rockefeller University, and informed consent was obtained from all subjects.
Apolipoprotein Preparation and Labeling
ApoA-I and apoA-II were prepared from healthy donor plasma by ultracentrifugation, delipidation, and column chromatography using standard methods. 9 Apolipoprotein purity was verified by sodium dodecyl sulfate-polyacrylamide gel electrophoresis followed by silver staining. The purified apoA-I and apoA-II were dissolved in 6 mol/L urea and 0.05 mol/L tris(hydroxymethyl)aminomethane, pH 8.5, at a concentration of 0.5 to 1.0 mg/mL for radioiodination by the iodine monochloride method and were tested for pyrogenicity and sterility. 
Kinetic Studies
The subjects were admitted to The Rockefeller University Hospital inpatient ward and kept on a metabolic diet consisting of commonly available foods for 4 weeks. The diet had a caloric distribution of 42% fat, 43% carbohydrate, and 15% protein. The total fat content corresponded to the 50th percentile of previous American intake according to the Lipid Research Clinics (LRC) study 18 and to the 75th percentile of current American consumption according to the second National Health and Nutrition Examination Survey (NHANES II). 19 Of total calories, polyunsaturated fat constituted 2%, monounsaturated fat 14%, and saturated fat 26%. Subjects consumed 215 mg cholesterol per 1000 calories. Caloric need was estimated by the Harris-Benedict 20 equation with adjustment for physical activity, 21 and caloric intake was not altered during the study. After the first 2 days body weight remained constant. Daily weights during the final 2 weeks were averaged, and the body mass index was calculated as weight in kilograms divided by the square of height in meters. No alcohol intake was allowed, and subjects were instructed to maintain their usual level of physical activity.
After 2 weeks of equilibration on the metabolic diet, the subjects received radioiodinated apoA-I and apoA-II (10 to 25 /i,Ci I-labeled apoA-I. Although one study 22 using labeling methods somewhat harsher than ours reported that radiolabeling of purified HDL apolipoproteins results in faster plasma removal than that obtained by protein labeling of intact HDL, subsequent studies in different laboratories 6 ' 23 ' 24 found that these two methods give comparable results. This similarity is due to the rapid association of free HDL apolipoproteins with plasma HDL in vivo. After bolus intravenous injection of tracer, blood was sampled at 10 minutes; 4, 12, 24, and 36 hours; and then daily until 14 days. Each sample was handled and counted as outlined. 9 Since all subjects had steady-state apoA-I and apoA-II levels, the radioactive decay curve was plotted directly from the die-away of plasma counts. FCR was calculated from this curve by the Matthews method. 25 Absolute TR was calculated by multiplying the FCR by the plasma pool (apolipoprotein level times plasma volume) and dividing by the subject's body weight. Plasma volume was determined by isotope dilution at the 0-minute point as calculated by loglinear backward extrapolation from the plasma content of tracer at the earliest sampling times.
To show that the iodinated apoA-I and apoA-II associated with HDL, in each study aliquots of plasma were taken 10 minutes and 7 and 14 days after injection. Three fractions (d< 1.063,1.063<rf<1.21, and d> 1.21 g/mL) were prepared by ultracentrifugation. The density distribution of radiolabel in these samples was calculated and averaged, providing a mea- sure of the density distribution of the subjects' own apolipoproteins. 6 ' 9 -2223 Since the percent tracer in the <i<1.063 fraction was very small (<2%) and varied little, the percent of tracer in either the HDL or the d> 1.21 g/mL fraction indicates the relative distribution between the two. Tracer in the d>\2\ g/mL fraction was predominantly within the 1.21 <d< 1.25 g/mL portion (very-high-density lipoprotein) in several representative subjects; therefore, the percent of tracer in the d>1.21 g/mL fraction was used as an indicator of the amount of lipid-poor very-high-density lipoprotein relative to more lipid-rich HDL.
Lipid, Lipoprotein, and Apolipoprotein Determinations
On days 1, 3, 7, 10, and 14 of the turnover period, plasma was obtained after a 12-hour overnight fast for measurement of lipid, lipoprotein, and apolipoprotein levels. Lipid and lipoprotein measurements were done on fresh specimens by enzymatic methods. 9 Aliquots of plasma were stored at -70°C for subsequent apolipoprotein determinations. ApoA-I levels were measured by a sandwich enzyme-linked immunosorbent assay using a polyclonal goat antibody to human apoA-I 9 generously supplied by Dr Peter Herbert of Yale University. ApoA-II levels were kindly determined by Dr John J. Albers in the Northwest LRC laboratories and by Dr Linda Bausserman at Brown University. Both laboratories used comparable radioimmunoassays based on a radial immunodiffusion assay. 26 Results from Brown correlated well with those from the LRC using split aliquots (r=.8, P<.01, slope=0.9, y intercept=-4 mg/dL). The coefficient of variation was approximately 8% within runs and 15% between runs for both the apoA-I and apoA-II assays. Over the 2-week turnover period, no temporal trends were observed in the lipid, lipoprotein, and apolipoprotein levels, and the means of all five determinations were used in the data analysis.
The molar ratio of HDL-C/apoA-I+apoA-II was calculated as an approximation of the core-to-surface ratio of HDL. The majority of cholesterol in HDL is esterified, and cholesteryl ester is the major constituent of the HDL core (unesterified cholesterol, a minor fraction of total HDL-C, is divided approximately evenly between the core and surface). The major surface constituents of HDL are apoA-I and apoA-II. Thus, the HDL-C/apoA-I+apoA-II ratio, an index of HDL composition, should also predict HDL size. This ratio correlates inversely with the percent of plasma apoA-I both in the d>1.21 g/mL fraction after ultracentrifugation (r=-.83, / > <.0001) and in particles smaller than albumin by gel filtration chromatography (r=-.61, P=.OO5) in human plasma samples (n=20) (E.A. Brinton and M.N. Nanjee, unpublished data, September, 1993).
Postheparin Lipase Activities
After 11 days on the test diet and 3 days before isotope injection, a postheparin lipase test was performed. After an overnight fast, the subjects were given an intravenous bolus dose of heparin, 60 U/kg body weight. Fifteen minutes later, a blood sample was taken and immediately chilled to 4°C. The plasma was promptly separated and stored at -70°C until assay. Lipase activity was measured with [ 3 H]triolein in a sonicated Triton X-100 emulsion in the presence or absence of rabbit anti-human lipoprotein lipase (LPL) serum. 9 Lipase activity was expressed as micromoles of free fatty acid liberated per milliliter of plasma per hour. LPL activity was the difference between total activity and that remaining after antibody inhibition, whereas the latter was the hepatic lipase (HL) activity. Because LPL and HL have opposing effects on HDL-C levels 27 (see Reference 28 for an earlier review) and because prior experience 10 with a subset of the subjects of the present study suggested the utility of combining LPL and HL data, the LPL-to-HL activity ratio was calculated and used in the statistical analyses.
Other Study Parameters
Truncal girth was measured with a narrow steel tape with the subject standing. The subject was instructed to push out the abdomen as far as possible and then allow it to relax. Girth was measured transversely at three levels, the first being the "minimum" girth, measured at end expiration at the level of intersection of the anterior costal margin with the midclavicular line. This usually constituted the minimum truncal girth. The second measurement was at the umbilicus, also made at end expiration after pushing out and relaxing the abdominal wall. The third measurement ("hip" girth) was made at the symphysis pubis, nearly always coinciding with the maximum posterior curvature of the buttocks. Care was exercised to maintain the tape completely horizontal (transverse), to maintain continuous contact with the skin, and to avoid compressing it inward. Girth was measured to the nearest millimeter, and two separate measurements were taken at each level by repositioning the tape in the opposite direction. If the first two measurements differed by more than 5 mm they were repeated until two measurements differing by no more than 5 mm were obtained. The mean of the two measurements at each level was used for calculating the minimum-to-hip ratio (MHR) and umbilicus-to-hip ratio (UHR), which were used for the statistical analyses. Measurements on 18 of the subjects were obtained during the turnover study. The remaining 39 subjects were measured from 3 months to 4 years later (average, 1 year); however, all but 8 of these subjects (Nos. 2, 13, 27, 28, 38, 43, 46, and 56) were measured within 5 kg of the study weight. Exclusion of these 8 subjects from analysis of girth ratio correlations did not alter the results. All but 12 subjects were measured by one of the authors (E.A. Brinton). The others were measured by other physicians or by the subjects themselves after careful instruction in the proper technique. Exclusion of the measurements not made by the authors did not alter the statistical correlations with other parameters.
Insulin concentration was measured in four fasting plasma samples taken during the final 2 weeks of the metabolic diet period for each subject; the samples were prepared and stored in the same way as for the apolipoprotein determinations. Insulin levels were kindly measured by Dr William Bauman of the Bronx Veterans Administration Medical Center by radioimmunoassay. 29 The results of duplicate assays on the four samples were averaged, and the mean value for each subject was used in statistical analyses.
All parameters (with exception of the truncal girth in some subjects as noted above) were measured during the steadystate metabolic diet period. .73
HDL-C indicates high-density lipoprotein cholesterol; Apo, apolipoprotein; FCR, fractional catabolic rate; LPL, lipoprotein lipase; HL, hepatic lipase; and TG, triglyceride. The independent variables are listed in descending order of strength of correlation from left to right. The probability value to add the variable is listed underneath the variable name, and the r and r 2 values for each stepwise combination of independent variables are given on the right. All independent variables adding at P<.05 are shown.
Statistical Analysis
Linear regression analysis was performed by using the least-squares method, and statistical significance was defined as a probability value of less than .05. Parameters that were log normally distributed (HDL-C, TG, and LPL-to-HL ratio) were logarithmically transformed for t test and linear regression analysis. Calculations were performed on The Rockefeller University Hospital CLINFO system. Results are reported as mean±SD.
Results
Levels of HDL-C and of its major apolipoproteins, apoA-I and apoA-II, were measured, along with other factors reported to relate to HDL-C levels. Men and women were compared to explore gender effects on HDL metabolism (Table 1) and to evaluate the appropriateness of pooling male and female subjects for other statistical analyses. Women had higher levels than men for HDL-C (56.7±21.4 versus 45.1±16.3 mg/dL, />=.O3) and apoA-I (147±32 versus 126±29 mg/dL, P=.til) but did not differ in apoA-II levels (34.5±7.4 versus 33.3±7.5 mg/dL, P>2). None of these levels varied during the study period. Women tended to have lower apoA-I FCR than men (0.248±0.077 versus 0.277±0.069 pools/d,/>=.l), although the difference did not reach statistical significance in the overall group, possibly due to subject heterogeneity. The gender difference in apoA-I FCR reached statistical significance only when subjects with normal HDL and TG levels (both between the 20th and 80th percentile for age and sex) were analyzed (0.277±0. Apo indicates apolipoprotein; FCR, fractional catabolic rate; HDL-C, high-density lipoprotein cholesterol; and UHR, umbilicus-to-hip ratio. The independent variables, probability values, and the r and r 2 values are given as noted for Table 2 .
versus 0.286 pools/d, / J =.OO7). In contrast, adjustment for other key parameters, including HDL-C/apoA-I+apoA-II, percent apoA-I in the d>1.21 g/mL fraction, TG LPL/HL, and UHR each eliminated the gender difference in apoA-I FCR (P=3 to .9), suggesting that they may mediate that difference.
Women also had a lower apoA-II FCR both in the overall group (0.184±0.043 versus 0.216±0.056 pools/d, P=.O2) and among the normolipemic subjects as well (0.171±0.031 versus 0.213±0.020 pools/d, P=.01). In contrast, women and men had equivalent apoA-I TR whether measured in the entire group (12.0±1.6 versus 12.1 ±2.8 mg/kg per day, P>.2) or among the subjects with normal HDL-C and TG levels (11.8±1.9 versus 11.7±3.5 mg/kg per day, P>2). The apoA-I TR of postmenopausal women differed neither from that of premenopausal women nor from that of men (12.4±1.1 versus 11.8±1.8 and 12.1±2.8 mg/kg per day for postmenopausal and premenopausal women and for men, respectively; P>.2). Women tended toward a lower apoA-II TR than men (2.19±0.62 versus 2.61 + 1.06 mg/kg per day, P=.O7). Although there was no significant gender difference in HDL size or density as estimated either by HDL-C/apoAI+apoA-II ratio (19.7±4.7 versus 17.8±3.9, P=.10) or by percent apoA-I tracer in the d>1.21 fraction (12.5±5.9 versus 14.5±7.9, P=3), both parameters tended to show smaller, denser HDL in men. Men and women did not differ in postheparin LPL activity (15.0±4.7 versus 15.2±5.8 !u,inol/mL per hour, P>.2), but women had far lower HL activity (13.7±5.9 versus 21.2±8.7 ^mol/mL per hour, P=.0003) and thus had a higher LPL/HL ratio (1.47±1.58 versus 0.92±0.70, P=.OO9 for log-transformed data). Fasting insulin levels did not differ significantly between female and male subjects (14.6±8.2 versus 11.6±4.2 /xU/mL, P=.10), but the women had a far lower MHR (.83±.1O versus .91±.O6, />=.0004) and a moder- ately lower UHR (.90±0.12 versus .95±0.06, P=M) than the men. Relations among these study parameters were explored by linear regression analysis. Despite the significant differences between men and women in some of these variables, the linear correlations among nearly all variables were similar between the genders, so data for men and women were pooled for regression analyses. There was a correlation between HDL-C and apoA-I levels (r=.87, P<.0001; Fig 1A) , but there was no significant relationship between HDL-C and apoA-II (r=.19, P=.\5; Fig IB) . We found a strong inverse correlation between HDL-C and apoA-I FCR (r= -.81, P<.0001; Fig 2A) and a similar relationship between HDL-C and apoA-II FCR (r=-.76, /><.0001; Fig 2C) . In contrast, there was no correlation between HDL-C and apoA-I TR (r=.O6, P>.2; Fig 2B) , and the moderate inverse correlation between HDL-C and apoA-II TR (r=-35, P=.01; Fig 2D) was diminished on exclusion of two outliers with extremely high apoA-II TRs (after exclusion, r=-.3O, P=.O3).
The study parameters were selected for reported relations with HDL-C levels, and such correlations were confirmed between HDL-C and the percent of the apoA-I and apoA-II tracers in the d> 1.21 g/mL fraction (r=-.46 and -.36, P<.0001 and <.001, respectively), fasting TG (r=-.59, /><.0001) and insulin (r=-.36, P=.OO7) levels, postheparin plasma LPL (r=.4O, =.002) and HL (r=-.5O, P<.0001) activities, LPL/HL ratio (r=.62, P<.0001), and UHR and MHR (r=-.52 and -.46, / ) <.0001 and <.001, respectively). Since each of these factors can potentially contribute directly to the regulation of HDL-C levels, we performed stepwise multiple linear regression analysis with HDL-C as the dependent variable and these other parameters as independent variables (excluding apoA-I and apoA-II levels). Dependent variables were added in descending order of univariate correlation with HDL-C. Two thirds of the variability in HDL-C was accounted for by apoA-I FCR (r 2 =.66; Table 2 ), with no additional contribution by the second strongest univariate correlate, apoA-II FCR. There was a modest addition from the third, LPL/HL (increasing r 2 to .71), and only a small addition by any other variable (r 2 increasing to .73 with fasting TG added to apoA-I FCR and LPL/HL). Since apoA-II FCR failed to add to the prediction of HDL-C by apoA-I FCR, correlations with apoA-II FCR were not pursued further.
Based on known physiological relations and data on HDL apolipoprotein turnover in patients with normal and low HDL-C, 10 we have hypothesized a hierarchical schema to interconnect various HDL-related parameters. 10 We sought to confirm and extend this model in the current study with a larger subject group, including subjects with low through high HDL-C levels, and with added study parameters. We studied each parameter from HDL downward as the dependent variable, using the remaining lower factors as independent variables. ApoA-I FCR was the strongest correlate of HDL-C levels among all the measured parameters, both in univariate and multivariate analyses. We next explored its possible determinants among the other study parameters. The best correlate of apoA-I FCR by single linear regression was the HDL-C/apoA-I+apoA-II ratio, an approximation of the core-to-surface ratio of HDL (see "Methods"), which had a strong inverse relation (r=-.81, P<.0001; Fig 3A) . The second best univariate correlate of apoA-I FCR was another parameter of HDL density or size, the percentage of the apoA-I tracer present in the d>\2\ g/mL fraction (r=.62, P<.0001; Fig 3B) . Although all of the other study parameters correlated with apoA-I FCR in univariate analysis, in stepwise multiple linear regression these first two parameters accounted for 70% of the variability in apoA-I FCR (r 2 =.7O; Table 3 ), and only a small increment in correlation was obtained by the addition of any other variable (r 2 =.72 with UHR; Table 3 ).
Since an estimate of HDL size by the HDL-C/apoAI+apoA-II ratio was the best predictor of apoA-I FCR, we next tested for predictors of this ratio to find possible determinants of HDL size. The best univariate predictors of the HDL-C/apoA-I+apoA-II ratio among the remaining study parameters were fasting plasma TG levels (r=-.74, .P<.0001; Fig 4a) and the LPL/HL activity ratio (r=.63, / > <.0001; Fig 4B) . In stepwise multivariate linear regression these both added to predict nearly three fourths of the variability in HDL-C/apoA-I+apoA-H (r 2 =.72; Table 4 ); the other remaining study parameters failed to add to its prediction. LPL and HL activities Umbilicus/Hip Girth Ratio correlated, directly and inversely, respectively, with the HDL-C/apoA-I+apoA-II ratio. LPL and HL taken simultaneously as two separate variables correlated approximately as well as did the LPL/HL ratio as a single variable.
Since the correlations of LPL and HL were consistently opposite each other, and because of their known opposing actions on HDL, to simplify our statistical analyses the LPL/HL ratio was used instead of the two separate variables. By univariate linear regression, fasting plasma TG was predicted both by fasting plasma insulin (r=.53, / > <.0001; Fig 5A) and by UHR (r=.52, P<.0001; Fig  5B) , and in multivariate linear regression analysis these two together predicted nearly one half of the variability in TG levels (r 2 =.46; Table 5 ). The LPL/HL activity ratio correlated with UHR (r= -.51, /><.0001; Fig 6) . In contrast to the other correlations between LPL/HL and the other parameters, in which LPL and HL both contributed to the relations seen with the LPL/HL ratio, the relationship between UHR and LPL/HL was due to HL alone (HL versus UHR, r= .52, P< .0001; LPL versus UHR, r = -. 3 , P=.15). In all other cases, both LPL and HL contributed to the prediction of other parameters by the LPL/HL ratio. Neither LPL/HL, LPL, nor HL correlated with fasting insulin (r=-.15, .03, and .22, respectively; P>.\).
Another goal of this study was to explore relationships between body fat distribution and HDL metabolism. Both UHR and MHR correlated well with HDL-C levels (/•= -.52, P<.0001 and r= -.46, /><.001, respectively), but since UHR appeared to correlate more strongly in this and other analyses, UHR alone was used as the parameter of body fat distribution. UHR also correlated well with the FCR of apoA-I (r=.61, P<.0001) and apoA-II (r=0.55, P<.0001) but only moderately or not at all with the TR of apoA-I or apoA-II (r=. 19, P= .2 and r= .29, P= .03, respectively). Thus, the amount of central (abdominal) fat relative to lower body (gluteal) fat directly relates to the fractional removal of the major HDL apolipoproteins .
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TG indicates triglyceride; UHR, umbilicus-to-hip ratio. The independent variables, probability values, and the r and r 2 values are given as noted for Table 2 .
from plasma. UHR also correlated with the HDL-C/ apoA-I+apoA-II ratio (r=-.59, P<.0001), the percent apoA-I tracer in the d>1.21 g/mL fraction (r=.36, P= .006), and fasting insulin (r= .37, P=.006) in addition to the previously mentioned relations with TG and lipase activity. Thus, the correlation of body fat distribution with HDL-C appears to be mediated by its proximate relations with TG, lipase, HDL size, and apoA-I FCR.
In summary, our earlier schema 10 was confirmed in a much larger and more diverse group of subjects. Furthermore, two new parameters, fasting insulin levels and body fat distribution, correlated with the other factors in a way confirmatory of their hypothesized contribution to lipoprotein metabolism. 13 The data in the current study are consistent with a new expanded schema (Fig 7) .
Individual data from each subject regarding apoA-I and apoA-II turnover and several related parameters are presented in Tables 6 through 9 . Subjects are divided by gender and ranked in descending order of HDL-C level. Table 6 presents subject age and lipoprotein levels; Table 7 , apolipoprotein levels and the turnover parameters FCR and TR; Table 8 , parameters of HDL size and postheparin LPL and HL activities; and Table 9 , fasting insulin levels, body mass index, and waist-to-hip ratios.
Discussion
The object of this study was to examine associations among parameters relating to HDL metabolism and to postulate mechanisms that might explain these associa- tions. We studied human subjects whose HDL-C levels varied across a broad range despite their consumption of identical metabolic diets. We measured several parameters in these subjects and tested for gender differences and for intercorrelation among the parameters.
Women are well known to have higher HDL-C levels than men, the average being about 55 mg/dL for women and about 45 mg/dL for men in Westernized societies. 30 We found similar mean values in the small, selected subject population of the current study, suggesting that our subjects may be representative of the general population. Nevertheless, because we selected for overrepresentation of extreme levels, the variability of HDL-C levels was much higher among our subjects than in unselected populations. We explored possible metabolic bases of the gender difference in HDL-C levels by unpaired t test. We found 17% higher apoA-I levels in women but a nonsignificant 3% difference in apoA-II levels, similar to previous reports. 6 The 17% elevation in apoA-I was associated with a nonsignificant trend toward a 10% reduction in its FCR in women, while its TR did not differ. ApoA-I TR did not differ between women and men even when postmenopausal subjects were excluded (1% and 3% lower than men with and without postmenopausal subjects, respectively). The lack of gender difference in apoA-II levels (3% higher in women) resulted from a 15% reduction in its FCR in women counterbalanced by a 16% reduction in its TR.
We further explored the relation of gender to apoA-I FCR by ANCOVA using key parameters from our linear regression analyses (Fig 7) . ANCOVA refines the study of differences in a primary or dependent variable (in this case, apoA-I FCR) between groups (women and men) by adjusting for covariates (the other key parameters) that correlate or covary with the dependent variable. In other words, by ANCOVA we asked whether women and men would differ in apoA-I FCR if they had equal values of a given covariate. With plasma insulin as the covariate, apoA-I FCR was a highly significant 16% lower in women (P=.OO7), strengthening our impression that women differ from men in apoA-I FCR. Interestingly, when we used any of the other key parameters (HDL-C/apoA-I+apoA-II, percent apoA-I in the d>\2\ g/mL fraction, TG, LPL/HL, or UHR) as a covariate, ANCOVA showed no gender difference in apoA-I FCR (P=3 to .9). However, rather than negating a gender difference in apoA-I FCR, these findings suggest possible mechanisms for that difference. Women and men differed (significantly or nearly so) in every one of these other key parameters in ways that should result in a lower FCR in women. This is suggestive evidence that one or more of these factors may cause apoA-I FCR to be reduced in women and may thus cause their HDL-C to be higher as well.
Our findings of a lower apoA-I FCR and the lack of an increase in apoA-I TR in women concur with those of Shepherd and coworkers, 12 who reported nonsignificant trends in women toward reduced FCR of apoA-I and apoA-II (13% and 10% lower, respectively) and reduced TR of apoA-I and apoA-II (both 6% lower). In contrast, Schaefer and colleagues 6 reported significant elevations of apoA-I and apoA-II TRs in women (22% and 20%, respectively) along with higher FCRs (a nonsignificant 8% increase for apoA-I and a significant 17% increase for apoA-II). Reasons for the major differences among these studies are unclear. Schaefer et al included only young adult subjects and had just over one third as many subjects as our study. However, we found no gender difference in apoA-I TR among subjects who were less than 49 years old (women, 11.8±1.8 versus men, 12.1±2.8 mg/kg per day, P>2), nor did we find a difference between our premenopausal and postmenopausal subjects (12.4±1.1 versus 11.8±1.8 mg/kg per day, P> .2). Furthermore, the lack of difference in apoA-I TR by gender was not due to our inclusion of subjects with a broad range of lipid levels because it did not differ by gender among our normolipemic subjects (women, 11.8+1.9 versus men, 11.7±3.5 mg/kg per day,
P>2).
Superficially, the elevated TR of apoA-I and apoA-II in women reported by Schaefer and colleagues 6 is confirmed by their later study, 31 which showed an increase in apoA-I TR during oral estrogen therapy. However, since endogenous estrogens enter the plasma outside of the portal circulation, the oral route is nonphysiological for estrogen replacement. Due to intestinal contact during enteral absorption and due to hepatic first-pass clearance, oral administration of estrogen in doses sufficient to provide physiological concentrations in the systemic circulation exposes both the small intestine and the liver to superphysiological concentrations of hormone. Since these two organs are the primary sites of apoA-I synthesis, it is plausible that such exposure could drive apoA-I production rates to artificially high levels. Other studies 32 in postmenopausal women confirmed that oral administration of estrogen may raise apoA-I TR, whereas parenteral (percutaneous) administration may have no effect. Despite the drawback that the parenteral estrogen was of insufficient dose or duration to reverse the expected postmenopausal reduction in HDL levels, the study 
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Two reports involving some of the subjects in the current study with elevated 9 or reduced 10 HDL-C levels clearly indicated that apoA-I FCR is a strong predictor of HDL-C. The current study, involving more subjects and covering the entire range of HDL-C levels seen in the clinical setting, establishes unequivocally that intersubject variability in HDL apolipoprotein FCR accounts far better for variability in HDL-C levels than do differences in HDL apolipoprotein TR. Of course, the metabolic parameters FCR and TR reflect only the average values for apoA-I and apoA-II molecules in each subject, while it is known that the apolipoprotein molecules travel on HDL particles that vary considerably in size and composition 33 and probably in their metabolic fate as well. 3435 Nevertheless, our data on the average metabolism of HDL apolipoproteins show that FCR is far better than TR as a predictor of variability in HDL-C levels. Other investigators reported similar findings, 5 -6 but due to smaller study size and narrower ranges of HDL-C levels, the importance of FCR was less clearly demonstrated.
A larger human HDL turnover study by Gylling and coworkers 8 suggested that apoA-I TR may predict apoA-I levels better than does apoA-I FCR (or its inverse, residence time). HDL-C levels, however, appear to be the best measure of HDL-related protection against atherosclerosis risk, and even in the Gylling study HDL-C was better predicted by apoA-I FCR than by apoA-I TR (r= .73,P<.002 versusr=.2,P>.2, respectively; n=44).
Multivariate analysis in the current study was particularly striking in demonstrating that the majority of variability in HDL-C levels between individuals can be accounted for by differences in apoA-I FCR, even when simultaneously evaluating many other physiological parameters known to correlate with HDL-C, including the FCR of apoA-II. While the correlation between apoA-I FCR and HDL-C does not prove that variability in apoA-I FCR regulates HDL-C levels in a causal sense, we hypothesize this to be so. The plausibility of this hypothesis is enhanced by the fact that essentially all HDL particles contain apoA-I. 33 Since cholesterol in HDL must associate with apoA-I, the fractional removal rate of apoA-I from plasma could regulate HDL-C levels. Thus, the FCR of apoA-I itself may be important as a causal factor of antiatherogenesis, or it may be related to other causal factors.
Average HDL size, as estimated by the HDL-C/ apoA-I + apoA-II ratio, may play a key role in determining apoA-I FCR, whether for subjects with elevated 9 or TC indicates total cholesterol; VLDL-C, very-low-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TG, triglyceride; Apo, apolipoprotein; FCR, fractional catabolic rate; TR, transport rate; LPL, lipoprotein lipase; HL, hepatic lipase; BMI, body mass index; Min, minimum girth; and Umb, umbilical girth.
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10 HDL-C. The current study extends this observation across the spectrum of HDL-C levels and more clearly establishes the relation by including an independent estimate of average density of apoA-I-containing particles, the percent of apoA-I tracer in the d>\.2\ g/mL fraction. We demonstrate that as much as 70% of the variability in apoA-I FCR may be attributable to variability in these estimates of HDL size or density. Horowitz and coworkers 36 confirmed the importance of the density distribution of apoA-I (as tracer or by mass) as a determinant of apoA-I FCR. Furthermore, the many other univariate correlates of FCR appear to have minimal or no relation with FCR aside from that explainable by HDL size alone (Table 3) . Thus, we believe that the contribution of TG levels, lipase activity, insulin sensitivity, and abdominal fat to FCR regulation is mediated by their contribution to regulation of average HDL size. Other researchers have shown relations between apoA-I FCR and LPL 37 - 38 and HL 337 activities but have not considered other aspects of HDL metabolism such as HDL size, which may serve as an intermediary for these relations. A third contribution of the current study is to further our understanding of the association between body fat distribution and HDL metabolism. Correlations between HDL-C levels and body fat distribution have been reported, the latter being primarily assessed by the waist-to-hip ratio (see Reference 13 for review). Thompson and coworkers 14 reported that chest skinfolds correlate positively with apoA-I FCR. The present study makes two additions to our understanding of this relation. We measured body fat distribution as the waist-to-hip ratio (or UHR) because this is widely considered to be the best anthropomorphic index of body fat distribution, and UHR was a strong inverse correlate of HDL-C among our subjects (r=-.52, P<.0001). UHR also correlated positively with apoA-I FCR (r=.61, P<.0001) and apoA-II FCR (r=.55, Z'<.0001). In contrast, there was little or no correlation of UHR with the TR of apoA-I (r=.19, P=2) or apoA-II (r=.29, /*=.O3). UHR also correlated with several parameters related to HDL metabolism, including HDL size as estimated by the HDL-C/apoA-I+apoA-II ratio (r=-.59, /><.0001), fasting TG (r=.52, /><.0001), and with the LPL/HL ratio, the latter being entirely through a correlation of UHR with HL (r=.52, / > <.0001). Interestingly, despite its strong univariate relations with HDL-C, apoA-I, and estimates of HDL size, in multiple linear regression UHR made no independent contribution to prediction of HDL-C or HDL-C/apoA-I+apoA-II and only a minor direct contribution to the prediction of apoA-I FCR. These data suggest that the relation of UHR with apoA-I FCR and estimates of HDL size is indirect and may be mediated through relations of UHR with TG, HL, and insulin levels. UHR may have a causal effect in regulating these three factors. 13 Excess abdominal fat may elevate TG levels by driving hepatic production of TG and very-low-density lipoprotein and perhaps by reducing peripheral lipolysis of TG-rich lipoproteins. 39 In contrast, the relationship between abdominal fat and HL activity may be indirect, since both can be increased by androgens. 37 Further delineation of these associations awaits additional studies.
Based on known physiological relations and data of the current study, the new version (Fig 7) of our earlier hypothetical schema 10 now includes fasting insulin levels and waist-to-hip ratio. We have tested these hypothesized interrelations by stepwise multiple linear regression, starting with HDL-C levels and working downward. Although all factors correlated, in univariate analysis, with all factors below them, each factor correlated best with the factor(s) directly beneath it. Furthermore, in multivariate analysis, prediction of any given factor was almost entirely confined to the factor(s) directly beneath it. All other factors lower on the schema added little or nothing to that relation. Thus, correlation analysis of our more extensive data set is consistent with our expanded schema, and we hypothesize that these intercorrelations may represent causal interrelations among the several atherosclerosis risk factors examined in the current study. Variability in HDL-C levels relates to and may result from variability in apoA-I FCR. ApoA-I FCR correlates best with variability in two estimates of HDL size (HDL-C/apoA-I+apoA-II and percent apoA-I in the d>l.2l g/mL fraction). HDL size may play a causal role in the regulation of apoA-I FCR (see Reference 36 for review). Control of HDL size may result from intersubject variability both in fasting TG levels and in lipase activity, expressed as the ratio of LPL/HL activity. Both LPL and HL help predict the estimates of HDL size. Since they relate oppositely to HDL-C levels and HDL size, a convenient index of their combined effects is the LPL/HL activity ratio. TG levels relate to fasting insulin levels, which are a strong inverse parameter of insulin sensitivity. We hypothesize that reduced insulin sensitivity, rather than hyperinsulinemia per se, contributes to elevated TG levels. Although we did not see a significant correlation between fasting insulin levels and the activity of either LPL, HL, or their ratio, others have reported such relations, 40 and so we have connected insulin and lipase with a dashed line in our schema (Fig 7) . Both TG levels and the LPL/HL ratio correlate with UHR (the latter predominantly through HL), and abdominal fat may contribute to control of the former and possibly the latter factors. 13 Although these mechanisms are not proven on the basis of the current study, our data are consistent with our schema. The known correlations of each of these factors with atherosclerosis may be mediated through the above proposed hierarchy of relations. The revised schema constitutes a hypothesis of a network of cause-effect relations among several physiological factors and HDL-C levels that we propose as a foundation for future research into the mechanisms of HDL metabolism and atherosclerosis.
